- Thermo Fisher Scientific has acquired Sanofi’s sterile fill-finish and packaging site in Ridgefield, New Jersey.
- The facility will continue to produce therapies for Sanofi while serving wider pharma and biotech manufacturing needs.
Thermo Fisher Scientific Inc. has completed its acquisition of Sanofi’s sterile fill-finish and packaging site in Ridgefield, New Jersey. The deal extends the companies’ strategic partnership and increases drug product manufacturing capacity in the United States.
Financial terms were not disclosed. The Ridgefield facility will now operate as part of Thermo Fisher’s pharma services business within its Laboratory Products and Biopharma Services segment. More than 200 employees from the site will join Thermo Fisher.
Under the agreement, Thermo Fisher will continue manufacturing Sanofi’s therapies at Ridgefield, while also opening the facility to other pharma and biotech customers seeking U.S.-based contract manufacturing services.
Marc N. Casper, Chairman, President and CEO of Thermo Fisher, said: “Bringing this world-class facility and team into our network strengthens our U.S. manufacturing capabilities to better support pharmaceutical and biotech customers, while positioning us for future expansion.”
The acquisition adds Ridgefield to Thermo Fisher’s U.S. sterile drug product network, which also includes sites in Greenville, North Carolina, and Plainville, Massachusetts.
